Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LOXO message board posts where the ticker symbol LOXO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LOXO SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-18-066990 (34 Act)  Size: 5 MB
2018-11-08 001-36562
181170122
8-K  Documents Current report, items 2.02, 5.07, 7.01, and 9.01
Acc-no: 0001104659-18-066801 (34 Act)  Size: 5 MB
2018-11-08 001-36562
181168077
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-003762 Size: 31 KB
2018-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-003760 Size: 23 KB
2018-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-003758 Size: 36 KB
2018-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-003657 Size: 11 KB
2018-10-03
8-K  Documents Current report, item 8.01
Acc-no: 0001104659-18-057044 (34 Act)  Size: 21 KB
2018-09-17 001-36562
181072374
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-002678 Size: 23 KB
2018-09-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-002677 Size: 35 KB
2018-09-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001567619-18-002676 Size: 29 KB
2018-09-14
More LOXO SEC Filings


Related news from
Thu, 08 Nov 2018
20:16:48 +0000
Edited Transcript of LOXO earnings conference call or presentation 8-Nov-18 1:00pm GMT
Q3 2018 Loxo Oncology Inc Earnings Call
Thu, 08 Nov 2018
13:45:01 +0000
Loxo Oncology (LOXO) Reports Q3 Loss, Lags Revenue Estimates
Loxo (LOXO) delivered earnings and revenue surprises of -3128.57% and -1.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 08 Nov 2018
12:39:24 +0000
Loxo: 3Q Earnings Snapshot
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 89 cents. Losses, adjusted for non-recurring gains, were $2.26 per share. The developer of cancer treatments posted revenue ...
Thu, 08 Nov 2018
11:45:00 +0000
Loxo Oncology Reports Third Quarter 2018 Financial Results
Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data Expected in 2019 LOXO-292 NDA Submission Expected in Late 2019.
Tue, 06 Nov 2018
11:45:00 +0000
Loxo Oncology to Participate in Upcoming Investor Conferences
STAMFORD, Conn., Nov. 06, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined.
Mon, 05 Nov 2018
13:05:15 +0000
See what the IHS Markit Score report has to say about Loxo Oncology Inc.
Loxo Oncology Inc NASDAQ NMS:LOXO
Mon, 05 Nov 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Loxo Oncology and Cronos Group
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / U.S. equities rolled back on Friday, ending a 3-day consecutive gain after confusing headlines about the trade talks with China. President Trump announced ...
Fri, 02 Nov 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Loxo Oncology and Auris Medical Holding
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
Thu, 01 Nov 2018
10:45:00 +0000
Loxo Oncology to Announce Third Quarter 2018 Financial Results
STAMFORD, Conn., Nov. 01, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined.
Tue, 23 Oct 2018
12:21:00 +0000
Why Investors Are Paying a Premium for These 3 Biotech Stocks
Here's how shares of these drugmakers surged to nosebleed valuations.
Mon, 22 Oct 2018
20:26:23 +0000
These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests
Mirati Therapeutics and Clovis Oncology dragged biotech companies into a pitfall Monday after studies of their cancer treatments disappointed during a meeting in Europe.
Sun, 21 Oct 2018
09:30:46 +0000
Roche takes on Loxo, Bayer in gene-defined cancer class
Roche's (ROG.S) entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer (BAYGn.DE) and Loxo Oncology (LOXO.O) in a new targeted treatment area. The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumour types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany's Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial.
Sun, 21 Oct 2018
09:12:00 +0000
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
- Median Duration of Response Not Reached With One Year of Additional Follow-up - - 67 Newly Reported TRK Fusion Patients Exhibit 81% ORR - STAMFORD, Conn., Oct. 21, 2018 --.
Sun, 21 Oct 2018
09:12:00 +0000
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
-- Median duration of response (mDOR) in primary dataset not reached after follow-up of 17.6 months(1) -- 18 percent of patients in the primary dataset experienced complete responses (CR), with the number ...
Fri, 19 Oct 2018
12:20:00 +0000
Research Report Identifies Loxo Oncology, Atrion, Alexander's, Broadridge Financial Solutions, International Flavors & Fragrances, and Conagra Brands with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tue, 16 Oct 2018
10:33:00 +0000
3 Biotechs Awaiting FDA Approval Decisions
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards